Monthly Musings Report on Pharma Sector July 2026 by Choice Institutional Equities
Regulatory Radar
Lupin
* USFDA approval: Eribulin Mesylate Injection (generic of Halaven), with alliance partner Natco Pharma, for metastatic breast cancer and liposarcoma.
* USFDA approval: Ranluspec (ranibizumab-hkdz), an interchangeable biosimilar of Lucentis, for multiple retinal disorders; the only US-approved interchangeable ranibizumab biosimilar available in both vial and pre-filled syringe formats.
* USFDA tentative approval: Enzalutamide Tablets, generic of Xtandi, for prostate cancer treatment.
Concord Biotech
* USFDA approval: Mycophenolate Mofetil Oral Suspension USP, an immunosuppressant used to prevent organ rejection in transplant patients.
* USFDA approval: Tofacitinib Tablets for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and other autoimmune disorders.
Aurobindo Pharma
* USFDA final approval: Tofacitinib Tablets (generic of Xeljanz) for autoimmune disorders; immediate US launch planned, targeting a ~USD 494 Mn market.
Alembic Pharmaceuticals
* USFDA final approval: Haloperidol Tablets USP (generic of Haldol) for psychotic disorders and Tourette's disorder; addresses a ~USD 27 Mn US market.
* USFDA final approval: Tretinoin Cream USP 0.05% (generic of Retin-A) for acne treatment; provides access to a ~USD 76 Mn US market.
* USFDA final approval: Oseltamivir Phosphate Oral Suspension (generic of Tamiflu) for influenza treatment and prevention.
* USFDA final approval: Dapsone Gel 5% (generic of Aczone Gel) for topical treatment of acne vulgaris.
* USFDA tentative approval: Larotrectinib Capsules for cancer treatment; first filer with potential 180-day generic exclusivity upon final approval.
* USFDA tentative approval: Binimetinib Tablets 45 mg for melanoma and certain lung cancers; sole first filer for the 45 mg strength with potential 180-day exclusivity upon final approval, targeting a ~USD 259 Mn market.
Astrazeneca Pharma India
* CDSCO approval: Additional indication for Enhertu (trastuzumab deruxtecan) in combination with pertuzumab as first-line treatment for patients with advanced HER2- positive breast cancer.
Facility Watch
Cipla
* Received USFDA Voluntary Action Indicated (VAI) classification following routine cGMP and Pre-Approval Inspection at its Verna, Goa manufacturing facility.
Dr Reddy
* USFDA Pre-License Inspection (PLI) at Bachupally biologics Imanufacturing facility concluded with seven Form 483 observations.
Concord Biotech
* ANVISA inspection at its Limbasi, Gujarat API manufacturing facility completed successfully.
* Joint Pharmacy and Poisons Board (Kenya) and National Drug Authority (Uganda) inspection at its Unit-II formulation facility completed successfully.
ZydUs
* Received USFDA Warning Letter for its Baddi formulation facility relating to purified talc not meeting current USP requirements; letter issued following records review with no expected impact on operations or supplies
Granules
* Received USFDA Establishment Inspection Report (EIR) for its Chantilly, Virginia facility with Voluntary Action Indicated (VAI) classification following inspection with four Form 483 observations.
Aurobindo
* USFDA classified Eugia Unit-III formulation facility in Telangana as Official Action Indicated (OAI) following inspection with eleven observations.
* USFDA Pre-Approval Inspection (PAI) at Eugia Steriles facility in Andhra Pradesh concluded with five observations.
* USFDA Inspection at its Andhra Pradesh API and formulation intermediates facility concluded with two observations.
Company Spotlight
Lupin
* Partnered with Laboratorios ERN to launch Luforbec in Spain for asthma and COPD treatment, expanding its respiratory franchise in Europe.
* Launched Azilsartan Medoxomil Tablets (generic of Edarbi) in the US with 180-day first-to-file exclusivity.
Zydus Lifesciences
* Completed acquisition of Assertio Holdings, strengthening its presence in the US specialty pharmaceuticals market.
* Partnered with Sunshine Healthcare to establish a pharmaceutical manufacturing facility in Sri Lanka through a joint venture with an investment of over USD 20 Mn.
* Extended closing date for acquisition of Sterling Biotech's API business to September 30, 2026
Dr. Reddy’s Laboratories
* Launched Bosutinib Tablets 400 mg (generic of Bosulif) in the US with 180-day generic exclusivity.
Sun Pharmaceutical Industries
* Acquired 100% stake in Innovcare Lifesciences for INR 271 crore in an all-cash deal, strengthening its presence in the nutraceuticals, cosmeceuticals and wellness segments.
Glenmark Pharmaceuticals
* Launched Lacosamide Injection USP (generic of Vimpat) in the US, expanding its injectable portfolio.
* Launched Winlevi across key European markets, marking its first New Chemical Entity (NCE) launch in Europe.
* Launched Methylene Blue Injection USP (generic of ProvayBlue) in the US, strengthening its institutional injectable portfolio
Piramal Pharma
* Received permanent revocation of closure directions for its Dahej facility from the Gujarat Pollution Control Board, removing the regulatory overhang.
IPCA Laboratories
* Entered global licensing agreement with Bhami's Research Laboratory for monoclonal antibody products targeting oncology and inflammatory diseases.
* Approved merger of Krebs Biochemicals & Industries, strengthening fermentation-based API capabilities and raw material security.
Marksans Pharma
* Acquired Netherlands-based QliniQ B.V., strengthening front-end presence and commercial infrastructure across regulated European markets.
* India Ratings revised outlook on bank facilities to Positive from Stable while reaffirming IND AA- /Positive/IND A1+ ratings, reflecting improving business profile and financial strength.
Alkem Laboratories
* Launched India's first single-shot pre-filled Semaglutide syringes for Type-2 diabetes and obesity, strengthening presence in the rapidly growing GLP-1 market.
* Executed supplementary agreement for acquisition of 51–55% stake in Switzerland-based Occlutech Holding AG through subsidiary Alkem Medtech.
Ajanta Pharma
* Promoter entity Ravi Agrawal Trust sold 2.76% stake through a block deal for INR 1,024 crore at INR 2,968 per share; shares were acquired by Kotak Mahindra Mutual Fund and Aditya Birla Sun Life Mutual Fund with 21.02 lakh and 13.47 lakh shares, respectively.
Concord Biotech
* Approved investment of INR 6.3 crore to acquire a 27.38% stake in FSGE Renewable Power Pvt. Ltd in a hybrid wind-solar power project to supply green energy to its Limbasi manufacturing facility.
Biocon
* Partner Duopharma Biotech secured insulin supply contracts worth over MYR 225 Mn from Malaysia's Ministry of Health, reinforcing Biocon's diabetes franchise
Strides Pharma
* Signed strategic investment deal with an Ascent Capital-led consortium in Pivot Path to realise ~INR 1000 Mn, enabling expansion and AI-led technology investments while retaining a ~20% stake and will inject INR 500 Mn of fresh capital.
Aurobindo Pharma
* Inaugurated TheraNym, one of India's largest biologics CDMO facilities, marking entry into the biologics contract manufacturing business with MSD serving as the anchor customer.
* Received US Federal Trade Commission clearance for acquisition of Lannett Company, with transaction expected to close by end of June 2026.
Alembic Pharmaceuticals
* Signed shareholders' agreement to acquire 45% stake in a Canadian joint venture alongside Difgen Holdings LLC, focused on pharmaceutical product development and commercialization.
For Detailed Report With Disclaimer Visit. https://choicebroking.in/disclaimer
SEBI Registration no.: INZ 000160131
